LENZ Therapeutics Inc

詳細情報 LENZ Therapeutics Inc 企業名

LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

企業情報

企業コードLENZ

会社名LENZ Therapeutics Inc

上場日Jun 25, 2021

最高経営責任者「CEO」Mr. Evert (Eef) Schimmelpennink

従業員数42

証券種類Ordinary Share

決算期末Jun 25

本社所在地- -

都市- -

証券取引所NASDAQ Global Select Consolidated

国- -

郵便番号- -

電話番号- -

ウェブサイト- -

企業コードLENZ

上場日Jun 25, 2021

最高経営責任者「CEO」Mr. Evert (Eef) Schimmelpennink

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. James Mccollum

Independent Director

620.60K

--

Mr. Marc Odrich

Chief Medical Officer

99.60K

--

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

+42.00%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

3.19K

--

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Ms. Shelley B. Thunen

Independent Director

--

Dr. Frederic (Fred) Guerard, Pharm.D.

Independent Director

--

Jeff W. George

Independent Chairman of the Board

--

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. James Mccollum

Independent Director

620.60K

--

Mr. Marc Odrich

Chief Medical Officer

99.60K

--

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

+42.00%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

3.19K

--

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sun, Aug 24

株主統計

種類

株主統計

比率

RA Capital Management, LP

14.65%

Alpha Wave Global, LP

12.66%

Versant Ventures

10.58%

Ridgeback Capital Management, L.P.

6.84%

Paradigm BioCapital Advisors LP

6.02%

他の

49.24%

株主統計

比率

RA Capital Management, LP

14.65%

Alpha Wave Global, LP

12.66%

Versant Ventures

10.58%

Ridgeback Capital Management, L.P.

6.84%

Paradigm BioCapital Advisors LP

6.02%

他の

49.24%

種類

株主統計

比率

Venture Capital

39.10%

Hedge Fund

27.55%

Investment Advisor

23.62%

Investment Advisor/Hedge Fund

13.97%

Individual Investor

2.73%

Research Firm

2.25%

Bank and Trust

0.14%

Pension Fund

0.06%

Insurance Company

0.02%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

245

29.52M

104.44%

-639.13K

2025Q1

245

28.95M

104.22%

-285.84K

2024Q4

225

27.65M

100.55%

-350.42K

2024Q3

204

26.43M

96.17%

-1.73M

2024Q2

197

25.06M

103.06%

+4.18M

2024Q1

204

22.41M

93.92%

+12.70M

2023Q4

200

7.73M

92.24%

-2.14M

2023Q3

200

7.54M

90.13%

-2.49M

2023Q2

212

7.64M

91.96%

-2.29M

2023Q1

205

7.41M

89.08%

-2.37M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

RA Capital Management, LP

4.18M

14.85%

--

May 07, 2025

Alpha Wave Global, LP

3.61M

12.83%

--

Apr 14, 2025

Versant Ventures

3.66M

12.99%

-884.80K

-19.48%

Jun 27, 2025

Ridgeback Capital Management, L.P.

1.95M

6.93%

--

Apr 14, 2025

Paradigm BioCapital Advisors LP

1.42M

5.04%

-92.10K

-6.09%

Apr 14, 2025

The Vanguard Group, Inc.

1.20M

4.25%

+21.02K

+1.79%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

1.05M

3.73%

-14.66K

-1.38%

Mar 31, 2025

Adage Capital Management, L.P.

537.74K

1.91%

+537.74K

--

Mar 31, 2025

72 Investment Holdings, LLC

1.02M

3.62%

--

Mar 31, 2025

Sectoral Asset Management Inc.

977.25K

3.47%

--

Mar 31, 2025

詳細を見る

41.690USD

LENZ Therapeutics Inc

41.690

概要

企業名

金融

分析